无需干扰素共同给药的基因型4丙肝治疗药物——Technivie

发布时间：2018-02-11 16:46

  本文关键词： Technivie ombitasvir paritaprevir 基因型丙型肝炎病毒　出处：《临床药物治疗杂志》2016年03期 　论文类型：期刊论文

【摘要】：Technivie由美国AbbVie制药公司研发,2014年FDA授予其突破性药物资格,并通过优先审查程序进行了审批,于2015年7月24日上市。该药由ombitasvir、paritaprevir、ritonavir复配而成,可直接口服给药。Technivie与利巴韦林合用是世界上首个无需使用干扰素的基因型4丙型肝炎治疗方案,它的出现使临床上基因型4丙肝的治疗产生了重大变化。笔者就Technivie的基本性质、作用机制、药动学、药效学、临床试验及应用等研发动态作一综述,以期能为医院临床用药起到指导作用。
[Abstract]:Technivie was developed by AbbVie Pharmaceuticals in the United States. In 2014, FDA awarded it a breakthrough drug qualification, which was approved through a priority review process and went on sale on July 24th 2015. The drug was prepared by a combination of ombitas virus paritaprevirr and ritonavir. The combination of ribavirin and .Technivie is the first genotypic hepatitis C therapy without interferon in the world. The research and development of mechanism, pharmacokinetics, pharmacodynamics, clinical trials and applications were reviewed in order to provide guidance for clinical use of drugs in hospitals.
【作者单位】： 国家应急防控药物工程技术研究中心军事医学科学院毒物药物研究所;
【分类号】：R512.63
，

本文编号：1503525